CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to NVO

biphasic insulin aspart

Phase 3
Novo Nordisk A/S (NVO)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

6

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Diabetes

Clinical Trial

NCT00280046

Last updated: 12/8/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMA4/25/2022

Truvelog Mix 30

Truvelog Mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.

View on EMA
EMA2/5/2021

Kirsty (previously Kixelle)

Kirsty is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

View on EMA
EMA6/25/2020

Insulin aspart Sanofi

Insulin aspart Sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

View on EMA
EMA1/9/2017

Fiasp

Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

View on EMA
EMA8/1/2000

NovoMix

Treatment of diabetes mellitus.

View on EMA
EMA9/7/1999

NovoRapid

NovoRapid is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.